Bionor Pharma’s Phase II Therapeutic HIV Vaccine Vacc-4x: Reboost Data Reconfirms 2010 Study (Oslo, Norway, 28 March 2014) Bionor Pharma ASA (OSE: BIONOR) announces the results from the Vacc-4x Phase II Reboost trial. The trial explored the effects of Vacc-4x revaccination or reboosting of HIV infected patients that participated in the large 2010 Phase II …
Bionor Pharma ASA announces that the Company has received approval from the Danish Regulatory Agency for its REDUC trial. The REDUC trial is a combination of Bionor Pharma’s lead vaccine candidate Vacc-4x and the Histone DeAcetlyase inhibitor (HDACi) Istodax®(romidepsin). Bionor Pharma further announces that the Company today has entered into a Supply Agreement with Celgene …
(Oslo, Norway, 24 February 2014) Bionor Pharma ASA (OSE: BIONOR) announces that results from its Phase I, first in man, trial of Vacc-C5. The trial met its primary endpoint which was safety. The trial also demonstrated that Vacc-C5 was able to generate C5 antibodies with effect of boosting, particularly in the top dose group. Increase …
